To minimize the impact of metabolic disorders, such as diabetes, dyslipidemia, and hepatic steatosis, on fetuin-A levels, we administered pioglitazone to healthy mice and investigated its effects on hepatic fetuin-A expression and circulating fetuin-A levels in vivo. This evidence concerns the gene AHSG and fatty liver disease.